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SUMÁRIO 
O cancro é uma das principais doenças no mundo que pode levar à morte. Por ano, 
milhões de pessoas são diagnosticadas e mais de metade morre com esta doença. 
Ao longo de várias décadas, diversos tratamentos alternativos à quimioterapia e 
radioterapia têm sido desenvolvidos no sentido de ultrapassar os problemas que estes 
tratamentos convencionais causam, nomeadamente os seus efeitos adversos associados 
com a sua elevada toxicidade sistémica. 
Uma das possíveis alternativas que o campo da investigação tem vindo a seguir 
direcciona-se para factores, alguns solúveis, segregados por bactérias como enzimas, 
metabolitos secundários, toxinas, proteínas e péptidos derivados, que actuam 
especificamente nas células cancerígenas, sendo potenciais agentes anticancerígenos 
(Yamada et al., 2002a; Bernardes et al., 2010). 
Um exemplo destes factores é uma pequena proteína solúvel em água, secretada 
por Pseudomonas aeruginosa, designada azurina com 128 aminoácidos e um peso 
molecular de 14 kDa (Yamada et al., 2005; Bernardes et al., 2013). 
Existem muitos factores que suportam o potencial existente para a azurina poder 
actuar como um agente anticancerígeno. Um deles é que esta entra preferencialmente em 
células cancerígenas (Yamada et al., 2005). Para além disto, após a sua administração, 
não foram observados efeitos secundários em estudos in vivo (Choi et al., 2011; Warso et 
al., 2013). Esta proteína bacteriana pode mediar interacções específicas de elevada 
afinidade com várias proteínas das células humanas, conferindo-lhe a propriedade de 
proteína “molde”, que é provavelmente uma das suas características mais importantes 
(Fialho et al., 2007). Esta capacidade para actuar em múltiplos alvos é importante devido 
ao facto de poder ser mais difícil as células cancerígenas adquirirem resistência a este 
tratamento. Outra vantagem é que a azurina é uma molécula solúvel em água com um 
domínio hidrofóbico, que pode contribuir para a sua entrada nos tecidos e na eliminação 
para a corrente sanguínea (Kamp et al., 1990). Por último, esta proteína pode ser 
facilmente superexpressa em Escherichia coli, o que torna os processos de produção e 
purificação muito mais baratos (Bernardes et al., 2013).  
O mecanismo de entrada da azurina nas células não é, no entanto, totalmente 
compreendido. Estudos sugerem que esta penetra a membrana plasmática por uma via 
endocítica mediada por caveolae, que são jangadas lípidicas não planares (Taylor et al., 
2009). As jangadas lipídicas têm concentrações elevadas de ácidos gordos saturados, de 
esfingolípidos (incluindo esfingomielina, ceramida e gangliósidos como o GM1), e de 
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colesterol (Quest et al., 2008; Martinez-Outschoorn et al., 2015). Estes microdomínios 
membranares são pequenos, dinâmicos, heterogéneos e conseguem recrutar certas 
classes de proteínas. Estão ainda implicados em vários processos celulares fisiológicos, 
tais como tráfico de proteínas pela membrana, transdução de sinal, transporte de 
colesterol, organização do citoesqueleto, motilidade, polaridade e endocitose (Simons and 
Toomre, 2000; Martinez-Outschoorn et al., 2015). Para além disto, sabe-se ainda que em 
melanomas e cancros da próstata e mama, as jangadas lipídicas estão em maior número, 
sugerindo que estas estruturas desempenham um papel funcional durante a tumorigénese 
(Irwin et al., 2011; Murai, 2015). Com isto, o estudo destas estruturas é importante para a 
prevenção e tratamento do cancro, uma vez que estas estão envolvidas na progressão da 
doença (Murai, 2015). 
Existem dois tipos de jangadas lipídicas: jangadas lipídicas planares, que não têm 
características morfológicas específicas, e jangadas lipídicas não planares que, como foi 
referido anteriormente, são as caveolae. No primeiro caso, a proteína constituinte destes 
microdomínios é a flotilina (Martinez-Outschoorn et al., 2015), enquanto que no segundo 
caso, são as caveolinas e as cavinas (Parton et al., 2006; Parton and del Pozo, 2013).  
Actualmente sabe-se que as caveolae tem um papel importante no cancro. Nestes 
microdomínios, a activação de cascatas de sinalização pode alterar a morfologia e o 
comportamento das células (Martinez-Outschoorn et al., 2015). A “hipótese de sinalização 
de caveolae” implica uma das suas proteínas constituintes obrigatórias, a caveolina-1, na 
integração de várias vias moleculares (Patani et al., 2012). A capacidade desta proteína 
em modular a sinalização intra-celular tem implicações importantes em vários estados 
patológicos e biológicos humanos, incluindo a tumorigénese. Na verdade, durante os 
últimos 20 anos, vários estudos foram feitos investigando o papel da caveolina-1 na 
iniciação e progressão do cancro, mostrando que esta proteína multifuncional regula 
diversos processos associados a esta doença, tais como transformação de células, 
crescimento de tumores, migração celular, invasão, resistência a múltiplas drogas e 
angiogénese (Senetta et al., 2013). 
A compreensão do papel da caveolina-1 no desenvolvimento e progressão do 
cancro pode ser significativa para melhorar o prognóstico do paciente e prevenir o 
aparecimento desta doença. 
Para além das vantagens da aplicação da azurina no tratamento do cancro 
descritas anteriormente, a utilização desta ou de péptidos seus derivados em combinação 
com fármacos quimioterapêuticos potencia o efeito anticancerígeno destes. Com isto, 
problemas como a aquisição de resistência ou toxicidade produzidos pela administração 
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sucessiva destes químicos podem ser ultrapassados, uma vez que passam a ser 
administrados em doses baixas (Bernardes et al., 2016; Yamada et al., 2016). 
Neste projecto de investigação, foram utilizadas três linhas celulares cancerígenas 
humanas: MCF-7 que corresponde a uma linha celular cancerígena de mama, HT-29 que 
é uma linha cancerígena de cólon e A549 que são células cancerígenas de pulmão. O 
objectivo principal deste trabalho é esclarecer o potencial anticancerígeno resultante da 
interacção entre a azurina com as jangadas lipídicas, decifrando o papel de caveolae. 
Neste estudo, demonstrámos que a azurina leva a um padrão de internalização das 
jangadas lipídicas, que consequentemente poderá remover receptores da superfície 
celular, que estão envolvidos na tumorigénese. Também verificámos que um dos 
primeiros passos de reconhecimento das células cancerígenas pela azurina dá-se ao 
nível do gangliósido GM1, que está localizado nas jangadas lipídicas. De seguida, 
observámos também que o silenciamento da expressão da caveolina-1 leva a uma 
diminuição, pelo menos em parte, da entrada da azurina nas células. Para além disso, foi 
possível verificar por técnicas de espectroscopia “in vitro”, que existe uma interacção 
física directa entra a azurina e um domínio funcional da caveolina-1, que é bastante 
importante na interacção com outras proteínas. O mesmo não se verifica para uma 
proteína mutante da azurina, onde foi operada a substituição de um aminoácido da sua 
estrutura nativa, identificando assim uma possível localização preferencial dentro da 
estrutura da azurina responsável pela interação desta com vários componentes dos 
microdomínios membranares. 
Por último, administrámos azurina em conjunto com fármacos quimioterapêuticos 
(paclitaxel e doxorrubicina) nas células cancerígenas, e observámos que no geral, a 
acção terapêutica destes é beneficiada, levando a maiores níveis de morte celular. 
Todos estes resultados elucidam sobre os mecanismos de entrada da azurina nas 
células cancerígenas, e mostram que esta proteína pode melhorar os efeitos de fármacos 
quimioterapêuticos que se encontram em uso clínico, e para os quais os doentes com 
cancro desenvolvem frequentemente resistência, dificultando a sua resposta terapêutica. 
 
 
 
 
Palavras-Chave: Azurina, Potencial Anticancerígeno, Jangadas Lipídicas, Caveolae, Fármacos 
Quimioterapêuticos. 
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ABSTRACT 
Azurin, a protein produced by Pseudomonas aeruginosa, acts as an anticancer 
agent. Studies suggest that this bacterial protein enters in cancer cells through the 
penetration of the plasma membrane via caveolae-mediated endocytic pathways. 
Caveolae are non-planar lipid rafts characterized by an abundance of caveolin and cavin 
proteins and it is known that the levels of lipid rafts are increased in melanomas, prostate, 
and breast cancers suggesting that these structures play a functional role during 
tumorigenesis. 
In this project, three human cancer cell models have been used: the MCF-7 breast 
cancer cell line, the HT-29 colon cancer cell line and the A549 lung cancer cell line with 
the main objective to clarify the anticancer potential of azurin interaction with lipid rafts, 
deciphering the role of caveolae.  
In this work, we demonstrate that azurin leads to a pattern of internalization of lipid 
rafts, through the staining of GM-1, a constituent of lipid rafts, with the Alexa488-labeled 
CtxB marker. We also show evidences that azurin recognizes cancer cells through the 
GM1 ganglioside which is located in lipid rafts, since its blockage with CtxB prevents the 
normal entry process of azurin in cancer cells. Then, we observed that silencing of Cav1 
expression leads to a decrease at least in part, on the entry azurin in cells. In addition, it 
was verified by spectroscopic "in vitro" techniques, that there is a direct physical 
interaction between azurin and a functional domain of Cav1, which is very important in 
interacting with other proteins. The same is not true for an azurin mutant protein, which 
was operated at an amino acid substitution of its native structure, identifying a possible 
region within the sequence of azurin that may be of major importance for this mechanism. 
Finally, we combined the azurin with chemotherapeutic drugs, such as paclitaxel 
and doxorubicin, and observed that in general, the therapeutic action of these is benefited, 
leading to higher levels of cell death than when the drugs are added alone. 
In general, all these results elucidate on the azurin entry mechanisms in cancer 
cells, and show that azurin may be relevant as an adjuvant to improve the effects of other 
anticancer agents already in clinical use, to which patients often develop resistance 
hampering its full therapeutic response. 
 
 
Keywords: Azurin, Anticancer Potential, Lipid Rafts, Caveolae, Chemotherapeutic Drugs. 
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1. INTRODUCTION 
Cancer is a major disease in the world that can cause death. Each year, millions of 
people are diagnosed worldwide with cancer, and more than half of these patients die from 
this disease. Based on World Health Organization projections, in 2030, the number of 
people expected to die of cancer will be around 11.4 million. In 2012, the most diagnosed 
types of cancer were lung (1.82 million), breast (1.67 million) and colorectal (1.36 million; 
Ferlay et al., 2014).  
This disease is characterized by uncontrolled cell growth (benign tumors) and 
acquisition of metastatic properties (malignant cancers). Frequently, this occurs due to the 
activation of oncogenes and/or deactivation of tumor suppressor genes leading to 
uncontrolled cell cycle progression and inactivation of apoptotic events. Mechanisms such 
as mutations, chromosomal translocations or deletions, and dysregulated expression or 
activity of signaling pathways are involved in these genetic and cellular changes. Recent 
studies also suggest that epigenetic alterations can cause cancer due to its role in the 
generation of cancer progenitor cells and subsequent initiation of carcinogenesis (Sarkar 
et al., 2013). 
This rising problem is mostly due to a rapidly aging population, and demands a 
coordinated response from oncologists, public health professionals, policy-makers and 
researchers. Conventional cancer treatments, such as chemotherapy and radiotherapy, 
often fail to achieve a complete cancer remission and they are likely to cause side effects. 
This has been stimulating the development of many new approaches for the treatment of 
cancer, such as the use of live or attenuated bacteria (Bernardes et al., 2010). 
The regression of cancer in humans and animals exposed to microbial pathogens 
agents has been verified more than 100 years ago (Yamada et al., 2002a). In 1909, 
William Coley used bacterial culture supernatants of Streptococcus pyogenes and Serratia 
marcescens to treat patients with malignant cancer. This preparation was administrated in 
approximately 1.200 patients leading to tumor regression in some cases, of which 30 
healed completely. Nowadays, it is assumed that the central factor responsible for this 
therapeutic effect was increased Tumor Necrosis Factor-α (TNF-α) secretion in the body of 
the patient (Karpiński and Szkaradkiewicz, 2013).  
Several reports have shown that microrganisms can replicate on the tumor 
locations, under hypoxic conditions (low concentration of oxygen), and also that 
microorganisms can stimulate the host’s immune system during the infections, blocking 
cancer progression (Yamada et al., 2002a).  
2 
 
Another example of a microbial pathogen strain that causes such effects is the 
Mycobacterium bovis, which already in 1976 was widely used in the treatment of 
superficial bladder cancer (Elkabani et al., 2000). Besides this, bacterial pathogens agents 
such as Listeria monocytogenes were tested as vaccine vectors for cancer prevention, 
since they induced the exposition of antigens on the cellular surface, leading to an immune 
response against cancer cells (Paglia et al., 1997). With this, it was believed that the 
infection with bacterial pathogen agents cause the activation of macrophages and 
lymphocytes, resulting in the production of cytotoxic agents with anticancer properties 
(Yamada et al., 2002a). However, the introduction of live bacteria on the human organism 
to treat cancer can produce significant side reactions, which may cause serious and 
eventually fatal infections that are presumed to be the resulted from the liberation of toxic 
bacterial products and limiting, that way, their use (Paglia et al., 1997; Dang et al., 2001). 
 
1.1. Bacterial protein azurin 
Currently, the investigation has been directed to segregated soluble factors by 
bacteria such as enzymes, secondary metabolites, proteins, or derived peptides and 
toxins, which may act specifically on cancer cells, being potential anticancer agents 
(Yamada et al., 2002a; Bernardes et al., 2010). An example of this factors is a small water-
soluble protein secreted by Pseudomonas aeruginosa, called azurin (14 kDa; 128 amino 
acids), which is composed by one α-helix and eight β-sheets, forming a β-barrel motif and 
contains a hydrophobic patch (Figure 1). This protein is part of a group of type I redox 
proteins, which have an ion copper in its constitution, named cupredoxins (Kamp et al., 
1990; Rienzo et al., 2000; Yamada et al., 2005; Fialho et al., 2012; Bernardes et al., 2013; 
Karpiński and Szkaradkiewicz, 2013). It is known that azurin is involved in the transport of 
electrons during the denitrification of these organisms (Yamada et al., 2009).  
 
 
 
 
 
 
Figure 1: Structure of azurin (Adapted from Karpiński and Szkaradkiewicz, 2013). 
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Azurin has structural similarity with variable domains of immunoglobulins and the 
ability to mediate specific high-affinity interactions with various unrelated mammalian 
proteins relevant in cancers, gives it the property of a natural scaffold protein (Fialho et al., 
2007).  
 
1.1.1. Entry mechanism of azurin on human cells and subsequent 
effects 
The mechanism of entry for azurin is still not fully understood. The first hints 
suggested that azurin enters in mammal cells through the penetration of the plasma 
membrane via caveolae-mediated endocytic pathways and reach late endosomes, 
lysosomes, and the Golgi associated with caveolae (Taylor et al., 2009). 
Currently, it is known that a peptide derived from azurin called p28 (50-77 amino 
acids) or Protein Entry Domain (PED) is per se, at least in part, responsible for mediating 
the entrance of the entire protein into cells. This peptide has an overall net negative 
charge, and forms an extended amphipathic α-helix with both hydrophobic amino acids 
(50-66) and hydrophilic amino acids (67-77). PED was further refined, by reducing the N-
terminal to amino-acids 50-67 (p18) and it was found that this minimal fragment can be 
translocated to the inside of human cancer cells (Yamada et al., 2005; Taylor et al., 2009). 
After the entrance of azurin to cancer cells, its derived peptide p28 is processed to 
the nucleus, it connects to a hydrophobic region inside of DNA-binding domain of tumor-
suppressor protein p53 (21 kDa; 393 amino acids), forming a complex, and with this it 
inhibits the proteasomal degradation of p53 (Yamada et al., 2009). This protein is involved 
in innumerous cellular processes, including transcription, DNA repair, genomic stability 
and cell cycle control, being able to induce cellular death by apoptosis.  In human cancers, 
p53 can suffer from inactivation by oncogenes and/or mutations (Martin et al., 2002; Apiyo 
and Wittung-Stafshede, 2005).  
Experiments with isothermal calorimetry demonstrated that azurin binds to the NH2-
terminal domain of p53 with nanomolar affinity in a 4:1 stoichiometry, as well to the DNA-
binding domain of this protein (Apiyo and Wittung-Stafshede, 2005).  
A few studies, supported by site-directed mutagenesis, suggest that a specific 
region of azurin has been implicated in this complex formation. This region consists in 
amino acids Met-44, Met-64 located in a hydrophobic patch, which have been shown to be 
important for the interactions with p53, and their substitutions resulted in altered complex 
formation (Yamada et al., 2002b). Thus, with the inhibition of proteasomal degradation of 
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p53 occurs a raise of the cytoplasmic and nuclear levels of this protein, and consequently, 
increased DNA binding activity. The cyclin-dependent kinase inhibitors p21 and p27 levels 
also increase, which in turn reduces the intracellular levels of Cyclin-Dependent Kinase 2 
(CDK2) and Cyclin A1, essential proteins in the mitotic process, as well as Forkhead box 
M1 (FOXM1), a transcription factor for G2/M progression. Since these components are 
involved in controlling the cell cycle, the reduction in their levels interrupts this process at 
G2/M phase, thus leading to apoptosis (Yamada et al., 2009). With this, it was possible to 
understand that the use of the p28 segment of azurin can be a good therapeutic option for 
the regression of tumors (Warso et al., 2013). It will then act like a cytostatic and cytotoxic 
agent, having yet been suggested that COOH-terminal of p28, with 10 to 12 amino acids, 
is responsible for its antiproliferative activity (Taylor et al., 2009). 
Additionally, it is documented that the azurin penetration rate into cancer cells 
decreases after the elimination of cholesterol on the plasma membranes using methyl-β-
cyclodextrin and after treatments with nocodazole or with monensin, which disrupt 
membrane caveolar by disruption of the microtubules and inhibit the activity of endosomes 
and lysosomes, respectively (Yamada et al., 2009). This suggests that this protein 
penetrates the plasma membrane via caveolae-mediated endocytic pathways. It is also 
known that this process is not dependent on membrane bound glycosaminoglycans 
neither on clathrins. This suggested that p28 and p18 penetrate the plasma membrane via 
a nonclathrin-caveolae-mediated process. In addition to all this, it is possible that N-
glycosylated proteins may have a role at least in the initial steps of recognition (Taylor et 
al., 2009). 
Beyond this, it is important to note that azurin shows a preferred internalization to 
the cancer cells rather than the normal ones. That way, the application of this bacterial 
protein on cancer therapy will bring a new way to fight this disease (Yamada et al., 2005). 
 
1.1.2. Azurin and cell surface receptors in cancer cells 
In 2014, Bernardes et al. revealed trough microarray analyses that in MCF-7 breast 
cancer cells treated with azurin occurred an up-regulation of genes associated with cellular 
processes, such as vesicle transport and pathways associated with lysosomes, as well as 
an increased expression of genes associated with endocytosis, membrane organization 
and endosome transport. Also, azurin caused a reduction in the expression of an important 
number of genes coding for cell surface receptors, as it was previously said, resulting in a 
down-regulating of their downstream signaling, which usually sustains cell proliferation and 
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aberrant constitutive signaling (Bernardes et al., 2014). It is known that cancer cells have 
the capability of grow, even in the absence of external growth stimulatory signals, 
frequently by overexpressing growth factor receptor tyrosine kinases (Hanahan and 
Weinberg, 2011). Some of these receptors, for example Epidermal Growth Factor 
Receptor (EGFR), when activated, stimulate signaling pathways involved in cell growth, 
survival and migration. EGFR is located normally on the plasma membrane, namely in 
discrete heterogeneous microdomains, denominated by lipid rafts, which are less fluid than 
the surrounding bulk plasma membrane, and enriched in cholesterol, sphingolipids and 
certain types of proteins, acting as platforms for cellular signaling. These microdomains 
are divided into two types: planar lipid rafts and non-planar lipid rafts. Levels of lipid rafts 
are increased in melanomas, prostate, and breast cancers, which suggests that these 
structures may play a functional role during tumorigenesis (Quest et al., 2008; Irwin et al., 
2011; Martinez-Outschoorn et al., 2015; Murai, 2015). The tyrosine kinase receptors can 
become extremely active by genomic amplification, overexpression or by mechanisms that 
inhibit their degradation upon their endocytosis. That way, this deregulation can lead to an 
excessive accumulation of these receptors on the surface of cancer cells (Abella and Park, 
2009). 
Azurin can also binds to several Eph receptor tyrosine kinases, a family of 
extracellular receptor proteins known to be upregulated in many tumors. This protein binds 
to the EphB2 receptor, interfering with its phosphorylation at the tyrosine residue, which in 
turn interferes with the binding to the ligand ephrinB2, resulting in the inhibition of cell 
signaling and cancer growth. It was suggested that such events occurred due to structural 
similarities between azurin and the ligand ephrinB2 (Figure 2; Chaudhari et al., 2007). 
 
In cancer cells, the removal of functional receptors from cell surface and their 
targeting to lysosome was proven to be an important mechanism by which their permanent 
activation and consequent tumorigenesisis are prevented (Abella and Park, 2009). 
Figure 2: Azurin can also bind avidly to the surface-exposed receptor tyrosine kinase EphB2, interfering in 
its binding with the ligand ephrinB2, and thereby preventing cell signaling that promotes cancer cell growth 
(Adapted from Bernardes et al., 2010). 
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1.2. Cholesterol effects in tumor progression  
Cholesterol is required for the assembly and maintenance of cell membranes and 
modulates membrane fluidity and function, including transmembrane signaling and cell 
adhesion to the extracellular matrix but various evidences also suggest that this steroid 
may play a critical role in cancer progression (Murai, 2015). 
One of the first observations linking cholesterol and cancer was made in 1909 in a 
study, which noted the presence of crystals of a ‘fatty nature’ in tumor sections (White, 
1909). Nevertheless, over 100 years later the cause and effect relationships between 
cholesterol and increased cancer risk remain unknown (Nelson et al., 2014). 
It was first noted in the early 1950s that obesity and elevated total cholesterol 
increase tumor incidence in mouse models of breast cancer. To clarify this issue, the 
impact of elevated cholesterol on breast tumor pathogenesis was evaluated in a mouse 
model, and thus found that a diet high in cholesterol but normal in fat content significantly 
decreased tumor latency and increased tumor growth, supporting the hypothesis that 
cholesterol itself can impact upon tumor pathophysiology (Nelson et al., 2014). 
Studies still demonstrated that malignant breast cells have the propensity to 
accumulate intracellular cholesterol, potentially seek cholesterol by invasion when their 
needs are not being met in their current environment. This may have implications for the 
control of progression and metastasis by regulation of dietary cholesterol (Martin and 
Golen, 2012). 
The maintenance of cholesterol homeostasis is a fundamental requirement for the 
normal growth of eukaryotic cells (Murai, 2015). Free cholesterol in most cells is 
maintained at a constant level by a series of homeostatic processes that regulate it: 
partitioning into the plasma and endoplasmic membranes; efflux, uptake, and de novo 
synthesis; esterification by acyl-CoA: cholesterol acyltransferase (Das et al., 2014). 
Given the complexity and redundancy of the mechanisms that regulate intracellular 
cholesterol homeostasis, it has been difficult to understand how an increase in circulating 
cholesterol can influence cancer pathogenesis. However, it is clear that under conditions 
of high cholesterol demand, as occurs during rapid proliferation, the cells should be able to 
overcome the processes that function to maintain cholesterol homeostasis. In particular, it 
has been demonstrated that activation of the T Cell Receptor (TCR) results in increased 
expression of SULT2B1, an enzyme that sulfates and inactivates the oxysterol ligands of 
Liver X Receptor (LXR). Consequently, the loss of LXRs activity, which is involved in 
maintaining intracellular cholesterol homeostasis, enables the cells to accumulate the 
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cholesterol needed for new membrane synthesis (Bensinger et al., 2008). It will be 
interesting to see whether cancer cells have adopted a similar mechanism to accumulate 
the cholesterol needed for cell proliferation (Nelson et al., 2014).  
Thus, cholesterol synthesis is tightly regulated in normal cells, but dysregulated 
cholesterol synthesis and sterol-dependent proliferation are frequently found in various 
cancer cell types, and may lead to cancer progression. In addition, proliferating cancer 
cells exhibit increased 3-Hydroxy-3-MethylGlutaryl-Coenzyme A reductase (HMG-CoA) 
and Low-Density Lipoprotein (LDL) receptor activities, resulting in increased cholesterol 
levels and higher cholesterol consumption compared to normal proliferating cells (Nelson 
et al., 2014). 
There are data suggesting that increased cholesterol content alters the biophysical 
properties of membranes, facilitating the formation of lipid rafts and increasing the activity 
of signaling events that initiate at the membrane (Nelson et al., 2014). 
As mentioned above, the levels of lipid rafts are increased in melanomas, prostate, 
and breast cancers suggesting that these structures play a functional role during 
tumorigenesis (Irwin et al., 2011; Murai, 2015). With this, the study of lipid rafts is 
important for the prevention and treatment of cancer, since these structures are involved in 
the progression of this disease (Murai, 2015). 
 
1.3. Lipid Rafts 
Lipid rafts (10-200 nm) have high concentrations of saturated fatty acids and 
sphingolipids (including sphingomyelin, ceramide and gangliosides like GM1), which are 
self-aggregate with cholesterol via interactions between their saturated hydrocarbon 
chains and the sterol ring of cholesterol. This specific composition results in a higher 
degree of organization of the lipid constituents in these membrane microdomains, known 
as the liquid ordered state (Quest et al., 2008; Martinez-Outschoorn et al., 2015). 
The most important properties of lipid rafts are that they are small, dynamic, 
heterogeneous, and can selectively recruit certain classes of proteins. These are 
implicated in various physiological cellular processes, such as protein membrane 
trafficking, signal transduction, cholesterol transport, cytoskeletal organization, motility, 
polarity and endocytosis (Simons and Toomre, 2000; Martinez-Outschoorn et al., 2015).  
As mentioned above, the gangliosides are characteristic components of the plasma 
membrane of eukaryotic cells, specifically located in lipid rafts (Margheri et al., 2015). GM1 
ganglioside has a special interest, since it is involved in the cellular signaling. Through 
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Figure 3: Two types of lipid rafts: Planar lipid rafts membrane (a) contain high concentrations of flotillin 
proteins, which bind to cholesterol and sphingolipids. These microdomains are in the same plane as 
the non-raft membrane, hence the term planar lipid rafts. Invaginated lipid rafts (b; caveolae) are not in 
the same plane as the rest of the plasma membrane, hence the term non-planar lipid rafts. Caveolae 
require caveolin and cavin proteins for their formation. CAV1 is caveolin-1 (Adapted from Martinez-
Outschoorn et al., 2015). 
interaction with this ganglioside, some biomolecules are endocytosed, triggering cellular 
functions such as microdomain regulation, ion transport modulation, neuronal 
differentiation, immune cell reactivity and neurotrophin signaling. The five glycosyl units 
forming the oligosaccharide chain of GM1 constitute a coding configuration that promotes 
selective interactions with other glycoconjugates as well as specific peptide sequences. 
The ceramide unit of this amphipathic molecule is also essential, because it maintains 
appropriate hydrophobic associations between GM1 and the lipid bilayer. Thereby, GM1 
has acquired the status of raft marker owing to its enrichment in lipid rafts and facile 
detection by ligands such as Cholera Toxin B subunit (CTxB) and anti-GM1 antibodies 
(Gonatas et al., 1983; Ledeen and Wu, 2015). 
There are two main types of lipid rafts: planar lipid rafts (Figure 3a) lack specific 
morphological features, as opposed to caveolae, which are non-planar lipid rafts (Figure 
3b). In the case of planar lipid rafts, these are constituted by flotillin proteins (Martinez-
Outschoorn et al., 2015). On the other hand, caveolae are characterized by an abundance 
of caveolin and cavin proteins (Parton and del Pozo, 2013).  
 
 
1.3.1. Caveolae and Caveolins  
Invaginated lipid rafts called caveolae have important roles in cancer. The activation 
of signaling cascades in this microdomain can change cell morphology and behavior 
(Martinez-Outschoorn et al., 2015). 
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Caveolae (from the Latin word for ‘little cavities’) were first described in the 1950s 
as 50-100 nm non-clathrin, flask-shaped invaginations of the plasma membrane, being 
rich in cholesterol, sphingomyelin and glycosphingolipids (Figure 4; Yamada, 1955; 
Senetta et al., 2013; Yang et al., 2015). 
 
The biological functions associated with caveolae are diverse. These include 
endocytosis, transcytosis, cell adhesion, cell migration, lipid regulation, 
compartmentalization of signaling pathways, calcium signaling and tumorigenesis (Razani 
and Lisanti, 2002; Parton and del Pozo, 2013; Anwar et al., 2015). Furthermore, caveolae 
can flatten in response to membrane stretch, providing a way to prevent rupture of the 
membrane. In addition, mechanosensing by this structure might induce protective 
downstream signaling responses, thereby regulating the composition of the Extracellular 
Matrix (ECM; Parton and del Pozo, 2013). Thus, caveolae interact with the actin 
cytoskeleton and microtubule network (Mundy, 2002).  
These non-planar lipid rafts can exist as invaginations of the plasma membrane, as 
completely enclosed vesicles or as aggregates of several vesicles. This led to the 
conclusion that these structures are conduits for the endocytosis of macromolecules 
(Razani and Lisanti, 2002). Interestingly, several studies have also shown that caveolae-
mediated uptake of materials is not limited to these molecules. In certain cell types, viruses 
and even entire bacteria are engulfed and transferred to intracellular compartments in a 
caveolae-dependent fashion (Anderson et al., 1996; Razani and Lisanti, 2002). Thereby, 
caveolae represent one of the multiple raft endocytic pathways. Furthermore, these 
structures contain some signaling molecules, such as G-proteins, non-receptor tyrosine 
kinases and endothelial Nitric Oxide Synthase (eNOS). These also function as organizing 
centers that concentrate key signaling transducers (Figure 5; Senetta et al., 2013). 
Figure 4: Caveolae: Electron micrographs showing the ultrastructure of caveolae in fibroblasts (main panel 
and at high magnification upper left), and the complex arrangements of caveolae in cultured adipocytes 
(upper middle) and in skeletal muscle (top right). Scale bars represent 100 nm (Adapted from Parton and del 
Pozo, 2013). 
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Recently, the fundamentals of caveolae biogenesis are beginning to be discovered 
(Parton and del Pozo, 2013). Caveolins, tightly bound to cholesterol and sphingolipids, are 
essential for caveola formation and they are the main integral proteins of this structure, in 
which they work together with another group of proteins termed cavins (Parton and del 
Pozo, 2013; Martinez-Outschoorn et al., 2015). Each caveolae contains approximately 100 
to 200 caveolin molecules formed by three principle members: Caveolin-1 (Cav1), 
Caveolin-2 (Cav2) and Caveolin-3 (Cav3; Fujimoto et al., 2000). The caveolin gene family 
is highly conserved with inter-species sequence homology (Patani et al., 2012) and 
includes CAV1, CAV2 and CAV3 genes. CAV1 is widely expressed in various tissues such 
as epithelial and endothelial cells, fibroblasts, adipocytes, and type I pneumocytes, and 
CAV2 shares a similar expression distribution to CAV1 as it requires CAV1 for 
stabilization. By contrast, CAV3 is specific to glia cells, skeletal and cardiac muscle cells 
(Scherer et al., 1994; Scherer et al., 1996; Tang et al., 1996; Martinez-Outschoorn et al., 
2015). The exception is smooth muscle cells, where all three proteins are produced (Tang 
et al., 1996).  
With the ability to form homo- and hetero-oligomers, caveolins directly interact with 
numerous proteins in plasma membrane and are involved in various signaling pathways 
(Anwar et al., 2015). 
The ‘caveolae signaling hypothesis’ implicates Cav1 in the integration of numerous 
molecular pathways (Patani et al., 2012). Cav1 in endothelial cells regulates angiogenesis, 
microvascular permeability and vascular remodeling (Hehlgans and Cordes, 2011). This 
protein facilitates transport of fatty acid and cholesterol in a lipoprotein chaperone complex 
as well as mediates transport of albumin and LDL through transcytosis pathway. Secretion 
of insulin is also mediated by Cav1 via ATP dependent-potassium channel and interaction 
with G-protein coupled receptor located at caveolae (Anwar et al., 2015). This protein also 
interacts with glycosyl-phosphatidylinositol-linked proteins (Patani et al., 2012), estrogen 
receptor (ER; Razandi et al., 2002), p85 regulatory subunit of PI3K and eNOS (Garcia-
Cardena et al., 1997; Ju et al., 1997). Furthermore, Cav1 has been reported to bind to 
several proteins involved in cell proliferation such as EGFR, Src-family tyrosine kinases, 
H-Ras, protein kinase C, components of the Mitogen-Activated Protein Kinase (MAPK) 
cascade and HER2/Neu (Figure 5; Zhang et al., 2013; Patani et al., 2012). The ability of 
Cav1 to modulate intracellular signaling has important implications in numerous human 
biological and pathological conditions, including tumorigenesis. Actually, during the past 20 
years, studies have investigated the role of Cav1 in cancer initiation and progression, 
showing that this multifunctional protein regulates many cancer-associated processes, 
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Figure 5: Structure and general activities of caveolae/caveolin-1. Caveolae are flask-shaped invaginations 
in the cell membrane coated with multimers of caveolin scaffolding proteins. The N-termini and C-termini of 
caveolin proteins are in the cell cytoplasm, but a hairpin loop of the protein is inserted into the cell 
membrane. Various caveolae/caveolin-1 activities that have been reported in different cell types are 
depicted. BMP, bone morphogenetic protein; MLC, myosin light chain; PI-3-kinase, phosphatidylinositol 3-
kinase; TGFβ, transforming growth factor beta (Baker and Tuan, 2013). 
such as cell transformation, tumor growth, cell migration, invasion, multidrug resistance 
and angiogenesis (Senetta et al., 2013). However, the relationship between Cav1 and 
tumorigenesis remains contentious (Patani et al., 2012). The observed expression profiles 
indicated that the role of Cav1 varied according to tumor types (Felicetti et al., 2009). 
Downregulation appears in ovarian cancer (Wiechen et al., 2001a), colon cancer (Bender 
et al., 2000) and mesenchymal sarcomas (Wiechen et al., 2001b). On the contrary, 
upregulation is associated with lung (Ho et al., 2002), bladder (Rajjayabun et al., 2001), 
breast (Anwar et al., 2015), esophageal (Kato et al., 2002), thyroid (Janković et al., 2012) 
and prostate cancers (Yang et al., 1999). Hence, inferences drawn from one cancer type 
may not be generalizable (Patani et al., 2012), because Cav1 apparently possesses 
mutually exclusive functions, as tumor suppressor or tumor promoting gene, depending on 
tumor type/stage, cell context and the deriving availability of Cav1 interacting partners 
(Felicetti et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cav1 is an integral membrane 178-amino acid protein of 21–22 kDa that was first 
identified in 1953 (Senetta et al., 2013). This protein is synthesized in the endoplasmic 
reticulum (ER), is shipped to the Golgi and finally, is transported to the cell surface to form 
caveolae (Quest et al., 2008). The CAV1 human gene is located on chromosome 7 in 
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region q31.1 at the D7S522 locus, which is close to a known fragile site (FRA7G) 
frequently deleted in cancer (Senetta et al., 2013). The molecular structure of Cav1 
resembles as a hairpin and the topology of this protein can be divided into domains (Figure 
6): a N-terminal Membrane Attachment Domain (NMAD; residues 1-60), an 
oligomerisation domain (residues 61-101) with a Caveolin-1 Scaffolding Domain (CSD; 
residues 82-101), a trans-membrane domain (residues 102-134) and a C-terminal 
Membrane Attachment Domain (CMAD; residues 135-178). Both the C- and N-terminal 
face the cytoplasm (Patani et al., 2012).  
Due to alternative splicing or initiation, Cav1 exists in two isoforms, α (residues 1-
178) or β (residues 32-178). Cav1β is distinct in that it has a 31 amino acid residue 
deletion at the amino terminus (Quest et al., 2008; Wang et al., 2015). 
Elucidation of Cav1 in cancer development and progression may be significant for 
improving patient prognosis and preventing tumor onset. 
 
 
 
 
 
 
1.3.2. Caveolin-1 Scaffolding Domain (CSD) 
The most prominent domain of Cav1 is the CSD (residues 82-101). Mutational 
studies indicate that this segment is necessary and sufficient for membrane binding 
(Schlegel et al., 1999). Nevertheless, these residues are also critical for oligomerization, 
protein interactions, and cholesterol recognition (Hoop et al., 2012).  
In an active form, Cav1 is frequently phosphorylated on tyrosine-14 and/or serine-
80 leading to activation of CSD (Anwar et al., 2015).  
Figure 6: The topology of caveolin-1 (Cav1), depicted as a homo-dimer, permits anchorage to the plasma 
membrane through a central hydrophobic domain, flanked by hydrophilic N- and C-terminal cytosolic 
domains (Adapted from Patani et al., 2012). 
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Residues within the CSD are required for oligomerization of Cav1 monomers into 
homo-oligomers of 14-16 proteins, which themselves assemble into higher-order 
oligomers during the formation of caveolae (Hoop et al., 2012).  
The F92TVT95 segment within the CSD is important for signaling, as it is required for 
interaction with other proteins, such as Src-family tyrosine kinases, H-Ras, HER2, 
estrogen receptor, MAPK and G protein-coupled receptors (Hoop et al., 2012; Wang et al., 
2015). This binding event involves a consensus motif in the partner protein with high 
aromatic content, occasionally referred to as a Caveolin-Binding Motif (CBM; Hoop et al., 
2012). The original definition of the CBM arises from the work of Couet et al., who 
obtained random peptides binding to the CSD by phage display. The peptides obtained 
were statistically enriched in tryptophan or other aromatic amino acids. Noting that certain 
separations of aromatic residues were particularly common, the investigators identified a 
16-residue portion of the bovine Gi2α subunit (the GP peptide) which bounds to CSDs 
from Cav1 and Cav3 and much less so to Cav2. Interestingly, when all four aromatic 
residues were simultaneously mutated to Alanine or Glycine, the interaction was lost. 
Based on this finding, three CBM variants were defined, each containing three or four 
aromatic residues separated by unspecified amino acids, and shown to occur in known or 
possible caveolin binding proteins. The aromatic residues of the defined CBMs are largely 
hydrophobic, especially phenylalanine (Couet et al., 1997). However, some studies 
suggest that the CBM, despite its prevalence in the caveolin literature, is not necessary for 
all caveolin interactions being only implicated in a small minority of events (Byrne et al., 
2012).  
Finally, the CSD facilitates direct interaction with cholesterol regulating raft 
organization and cholesterol trafficking (Tagawa et al., 2005). More precisely, formation of 
caveolae strictly requires tight binding of Cav1 to cholesterol (Murata et al., 1995). This 
functionality is localized to a Cholesterol Recognition/interaction Amino acid Consensus 
motif (CRAC; residues 94-101) in residues V94TKYWFYR101 (Figure 7; Epand et al., 2005).  
Thus, despite its short length (20-residue segment), the CSD appears to incorporate 
an array of critical functionalities (Hoop et al., 2012). 
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In summary, future studies are needed to unravel the relationship between lipid rafts 
and the adhesion and migration capacity of cancer cells, and to clarify the anticancer 
potential of azurin interaction with lipid rafts, deciphering the role of caveolae. Studies on 
the regulation of cholesterol are also important to understand the mechanisms related to 
cancer progression. With this, new targets may be developed for the treatment and 
prevention of cancer.  
 
1.4. Azurin application in the treatment of cancer 
There are many reasons which support the theory that azurin have the potential to 
act as an anticancer agent. Besides the preferential entry in cancer cells, no adverse side 
effects were observed in vivo studies (Yamada et al., 2005; Choi et al., 2011; Warso et al., 
2013). As mentioned above, this protein also can mediate specific high-affinity interactions 
with various unrelated mammalian proteins relevant in cancer, conferring on it the property 
of natural scaffold protein, which is probably the most important characteristic of this 
protein (Fialho et al., 2007). This ability to act on multiple targets is important due to the 
fact that might be harder to trigger resistance by the cells. Another advantage of this 
bacterial protein is that azurin is a water-soluble molecule with a hydrophobic patch, and 
this might help in its tissue penetration and clearance from the blood stream (Kamp et al., 
1990). In addition to all this, azurin can be easily hyper-expressed in Escherichia coli, 
which makes the process of production very cheap (Bernardes et al., 2013), and being a 
Figure 7: Amino acid sequence of caveolin-1 (Cav1). The topology of this protein can be divided into 
domains: an oligomerization domain (residues 61-101; black and blue) with a caveolin scaffolding domain 
(CSD; residues 82-101, blue), a trans-membrane domain (residues 102-134; red) and bold residues indicate 
the C-terminal membrane attachment domain (CMAD; residues 135-178) and the N-terminal membrane 
attachment domain (NMAD; residues 1-60). The CSD also contains cholesterol recognition/interaction amino 
acid consensus (CRAC; Adapted from Hoop et al., 2012). 
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small protein it can be hypothesized that it expression may occur in different vectors, 
including some human cell types. All these reasons make azurin an attractive molecule to 
be used in cancer therapy. 
Preclinical pharmacological studies recurring to the use of p28 provided significant 
evidences that there is no apparent toxicity or immune response in the patients with solid 
tumors p53+/+, on which No Observed Adverse Effect Level (NOAEL) and Maximum 
Tolerated Dose (MTD) were established (Warso et al., 2013). With these results, it can be 
concluded that azurin has low immunogenicity, being a non-antibody recognized protein 
and for that, it is not susceptible to immune attack, even though it is a bacterial protein. 
p28, as a lead compound supported by CDG Therapeutics, has finished Phase I 
clinical trial, which defined it as an anticancer agent under an investigational new drug 
application (IND 77.754) approved by the Food and Drug Administration (Bernardes et al., 
2013). Recent studies have also shown that p28 is safe and well tolerated in children with 
progressive CNS malignancies (Lulla et al., 2016). Subsequent studies will focus on the 
establishment of an adequate dose for Phase II clinical trial, in obtaining a 
pharmacokinetic profile, determining potential immunogenicity and if possible assessing 
preliminary antitumor activity (Warso et al., 2013).  
However, there are other domains in azurin with anticancer property (Chaudhari et 
al., 2007) that should provide better efficacy and will likely make azurin less susceptible to 
resistance development provided lack of toxicity of azurin in animals and cancer patients 
can be demonstrated, as has been done for p28 (Fialho and Chakrabarty, 2012). 
Given azurin’s propensity for both therapeutic and cancer preventive activity, a 
weekly or bi-weekly injection of azurin in vulnerable people, for example women with 
family history of breast or ovarian cancers and with diagnosed BRCA1/BRCA2 mutations, 
may be one way to prevent, or greatly reduce, the onset of cancer in such people. Other 
pathways of administration azurin for cancer treatment, such as oral are currently being 
investigated (Chakrabarty et al., 2014). 
The p28 segment of azurin or the entire protein can be combined with drugs, 
resulting in the transport of these to the interior of cancer cells. For example, p28 can be 
combined with cargo proteins, which cannot enter by themselves in eukaryotic cells 
(Yamada et al., 2005), or nanoparticle-loaded drugs can be surface coated with azurin to 
improve its therapeutic efficiency. In addition, azurin or its derived peptides can be 
fluorescently labeled, providing good diagnostic markers to locate tumors inside the body, 
since it preferentially moves toward cancer cells (Chakrabarty et al., 2014). 
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1.4.1. Effects of azurin treatment in combination with drugs on human 
cancer cells 
Nowadays, chemotherapeutics include DNA-damaging and antimitotic agents. The 
first intercalate with DNA, inducing double strand breaks that induce ataxia-telangiectasia 
mutated (ATM)-dependent nuclear accumulation of p53 (Kurz et al., 2004). In addition, the 
apoptotic pathway via Bcl-2/Bax and the caspase cascade, as well as the necrotic 
pathway through Toll-like receptors are targets for DNA-damaging agents (Yamada et al., 
2016). On the other hand, antimitotic agents bind to the β-tubulin subunits of microtubules. 
This interaction leads to a prolonged activation of the mitotic spindle checkpoint and 
mitotic arrest followed by mitotic slippage and induction of apoptosis. This agents, also 
called taxanes, still induce post-transcriptional acetylation and phosphorylation of p53, 
which leads to its intracellular increase, upregulating p21 protein, inhibiting the cell cycle, 
and also leading to apoptosis (Kim et al., 2013).  
Unfortunately, with the consecutive application of these agents, cancer cells acquire 
resistance. Beyond this, these drugs can also lead to significant toxicity that may force 
treatment to become dose-limiting (Yamada et al., 2016). With this, new therapeutic 
strategies, more effective in killing cancer cells but also more selective, are needed in 
order to increase the efficiency and decrease the toxic side effects associated to 
administration of drugs (Bernardes et al., 2016). 
One of these strategies is based on simultaneous use of the p28 peptide derived 
from azurin or the protein with drugs. 
Recent studies have shown that p28 in combination with lower concentrations of 
DNA-damaging drugs like doxorubicin, dacarbazine, temozolamide, and antimitotic agents 
such as paclitaxel and docetaxel, increased their cytotoxicity by activating tumor-
suppressor protein p53, which subsequently induced the endogenous cyclin-dependent 
kinase inhibitor p21, reducing levels of CDK2, resulting in cell cycle inhibition at G2/M 
phase and leading to apoptosis. Thus, the enhanced activity of these anticancer agents in 
combination with p28 was facilitated through the p53/p21/CDK2 pathway. Taken together, 
these results highlight a new approach to maximize the efficacy of chemotherapeutic 
agents while reducing dose-related toxicity (Yamada et al., 2016). 
In addition, a recent study also assessed the potential synergy of a co-treatment 
with azurin. The drugs used were gefitinib or erlotinib, both EGFR inhibitors, in low 
concentrations. These combined treatment demonstrated an increase in cell death when 
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compared to the sum of each agent alone, i.e., a synergistic effect occurred in comparison 
to the single treatments (Bernardes et al., 2016).  
In the same study, it was demonstrated by Atomic Force Microscopy that azurin 
administration leads to changes in biophysical properties of the plasma membrane of 
cancer cells, thereby causing changes in signaling pathways that mediate drug resistance. 
These effects may be of particular interest in drug resistant cancers, where the more rigid 
nature of the membrane was associated to increased resistance to the accumulation of 
anticancer drugs. Therefore, since azurin may disrupt lipid rafts, the effects of co-
administrated drugs are enhanced (Bernardes et al., 2016). 
Another study demonstrating the mentioned above was performed by Choi et al., 
2011. In this study, azurin-treated oral squamous carcinoma cells showed decreased cell 
viability accompanied by apoptotic phenotypes including morphological change, DNA 
breakage, and increases in p53 and cyclin B1 protein levels. In these cancer cells, with 
combined treatment of azurin and anticancer agents (5-fluorouracil and etopside), they 
discovered that this protein increased the sensitivity of oral squamous carcinoma cells to 
these anticancer drugs (Choi et al., 2011). 
In conclusion, azurin has a strong enhancer anticancer effect on cancer cells when 
it is used along with anticancer drugs. 
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2. OBJECTIVES AND THESIS OUTLINE 
Several studies have shown that caveolae, a non-planar lipid raft, have an important 
role in cancer. These can exist as invaginations of the plasma membrane, as completely 
enclosed vesicles or as aggregates of several vesicles. This led to the conclusion that 
these structures are conduits for the endocytosis of macromolecules (Razani and Lisanti, 
2002). In addition, it is known that the essential components for the formation of caveolae 
are caveolins (Cav1, Cav2 and Cav3), which are tightly bound to cholesterol and 
sphingolipids (Parton and del Pozo, 2013; Martinez-Outschoorn et al., 2015). In the case 
of Cav1, the ability of this protein to modulate intracellular signaling has important 
implications in numerous human biological and pathological conditions, including 
tumorigenesis (Senetta et al., 2013).  
Besides this, previous studies suggest that azurin enters in mammal cells through 
penetration the plasma membrane via caveolae-mediated endocytic pathway (Taylor et al., 
2009). 
With all this, this research project aims to clarify the anticancer potential of azurin 
interaction with lipid rafts, deciphering the role of caveolae. Moreover, recent studies from 
our group suggested that the link between the Cav1 and azurin involves a consensus motif 
rich in aromatic amino acids in azurin, occasionally referred to as a CBM (unpublished 
data). This led to the hypothesis that this hot-spot of aromatic amino acids are critical to 
the first recognition steps between azurin and cancer cells. To understand the importance 
of these aromatic residues in azurin interaction with cancer cells, a mutation in this region 
was made and the interaction of this mutated azurin with cancer cells was studied. It was 
shown that mutated azurin has a reduced entry capacity in cancer cells.  Furthermore, the 
levels of Cav1 in cancer cells upon treatment with the mutated azurin were also studied, 
showing that the mutated protein cannot decrease Cav1 content like the WT azurin. By 
invasion and MTT assays, it was shown that this mutated protein cannot decrease 
significantly invasion and cell viability like the WT azurin. These data showed that this 
mutation in one particular residue of azurin sequence plays an especially important role in 
the entry process of azurin, since a  mutation  in  that  residue affected the  ability  of  this  
protein  to enter  and exert his cytotoxic effects in cancer cells (unpublished data). Due to 
all these results, the mutated azurin was also used in the development of this work. 
We started to observe if human cancer cells treated with azurin alter their lipid raft 
staining profile through immunostaining with a fluorescent-labeled for CTxB. 
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Next, we investigated whether the GM1 ganglioside has an important role in the 
recognition of azurin, before this protein is endocytosed by the cancer cells. As mentioned, 
the GM1 has acquired the status of raft marker owing to its enrichment in lipid rafts and 
facile detection by ligands such as CTxB and anti-GM1 antibodies (Ledeen and Wu, 
2015). Thereby, we performed entry assays with WT azurin and mutated protein, being the 
cancer cells previously treated with CTxB, blocking the function of GM1 ganglioside. 
Another experiment carried out in this project was based on Cav1 silencing in order 
to verify the effect it produces in the levels of entry of azurin in the cancer cells treated.  
The occurrence of an effective binding between azurin and CSD, which is the most 
prominent domain of Cav1, was also examined. In this experiment, it was also used the 
mutant protein to conclude whether this region of azurin is or is not essential in this bond. 
Finally, we investigated whether the azurin, besides acting in caveolae, also acts on 
planar lipid rafts. 
On the other hand, to verify if the application of azurin with drugs leads to a 
enhancer anticancer effect on cancer cells, these were treated simultaneously with the 
protein under study and with anticancer agents such as paclitaxel (antimitotic agent) and 
doxorubicin (DNA-damaging drug).  
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3. MATERIALS AND METHODS  
3.1. Human cancer cell lines and cell cultures 
Three human cancer cell models have been used: the MCF-7 breast cancer cell 
line, the A549 lung cancer cell line and the HT-29 colon cancer cell line. These cell lines 
were purchased from European Collection of Authenticated Cell Cultures. All of them were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco® by Life Technologies), 
supplemented with 10% of heat-inactivated Fetal Bovine Serum (FBS; Gibco® by Life 
Technologies), 100IU/mL penicillin and 100mg/mL streptomycin (PenStrep, Invitrogen). 
These cell lines were passed between 2 to 3 times per week, by chemical detaching with 
0.05% of trypsin. 
MCF-7, HT-29 e A549 human cancer cell lines were grown at 37ºC in a humidified 
chamber containing 5% of CO2 (Binder CO2 incubator C150). This temperature is similar to 
in vivo environment that those are exposed and this carbon dioxide concentration allows to 
maintain the pH of the culture medium. 
 
3.2. Bacteria growth, over-expression, extraction and purification of WT 
azurin or mutated protein 
The continuous production of azurin was performed as described in Bernardes et 
al., 2013. It was made a pre-inoculum in a 250mL Erlenmeyer flask with 100mL of Luria 
Broth medium (LB medium), 100μL ampicillin in a concentration of 150µg/mL and an 
inoculum of Escherichia coli SURE strain. This strain has a deficiency in the expression of 
proteases, thus suitable for protein overexpression. This has previously been cloned with 
the plasmid pWH844, containing the azu gene or carrying the mutation, from 
Pseudomonas aeruginosa PAO 1, which is responsible for the synthesis of azurin. This 
culture was grown overnight, at 37ºC, in an agitator at 250 rpm. 
On the previous day, the culture was grown in 3L Erlenmeyer flasks containing 1L 
of Super Broth medium (SB medium; 20g/L of yeast extract, 32g/L of triptone and 5g/L of 
NaCl) supplemented with ampicillin in a final concentration of 150µg/mL. The volume of 
the pre-inoculum was calculated in a way that the initial culture has an optical density at 
640nm (OD640) of 0.1. The optical density readings of culture media were carried out in a 
spectrophotometer. The growing conditions are the same of the pre-inoculum. When the 
culture reached an OD640 of 0.6-0.8, that corresponds to exponential phase of growth, the 
WT azurin or mutated protein expression was induced with 0.2mM or 0.5mM of IsoPropyl-
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β-D-ThioGalactopyranoside (IPTG-inductor of azurin’s promoter; Sigma Life Science) 
respectively, for 4-6 hours, at the same agitation and temperature. After this time, cells 
were recovered by centrifugation (8.000 rpm, 10 minutes, 4ºC; Beckman J2-MC 
Centrifuge), and the resulting pellet was ressuspended in 15mL of Start buffer (10mM 
imidazole, 0.2mM sodium phosphate, 0.5M NaCl, pH 7.4), and stored at -80ºC until 
azurin’s purification. 
In order to purify azurin, cells were disrupted (mechanical lysis of cell walls and 
membranes) by sonication (Branson Sonifier Sound Enclosure 250). These were 
centrifuged (17.600xg, 5 minutes, 4ºC; B. Braun Sigma-Aldrich 2K15) and then, were 
removed debris. After that, the pellet was discarded. The supernatant was again 
centrifuged in the same conditions for 1 hour.  
The azu gene was cloned into a plasmid with nucleotide sequence corresponding to 
a histidine tag (6Xhis). Therefore, it was used a histidine affinity column (HisTrapTM FF, GE 
Healthcare) to purify azurin, that was eluted with increase in the concentrations of 
imidazole (20-500mM). Azurin is eluted in concentrations of 100-300mM of imidazole. 
Next, the buffer rich in imidazole was exchanged to Phosphate Buffered Saline (PBS; 
137mM of NaCL, 2.7mM of KCl, 4.3mM of Na2HPO4.2H2O and 1.47mM KH2PO4) in ÄKTA 
system (ÄKTA Prime, Amersham Biosciences) with a desalting column (HiPrepTM 26/10 
Desalting, GE Healthcare). The collected protein was concentrated by centrifugation 
(5.000 rpm, 4ºC; Eppendorf Centrifuge 5804R) in a 3kDa cut-off column. The final volume 
of purified protein was centrifuged in a 100 kDa cut off filter, to remove eventual 
contaminants. 
The concentration of azurin was estimated according to the absorbance at 280nm, 
using the Lambert-Beer equation, where ε280 = 9.1 x 103 M-1 cm-1 (Amsterdam et al., 2002). 
To verify if azurin had any contamination, a test spot was performed overnight at 37°C 
(two spots with 10μL of azurin in a LB agar plate). Azurin was stored at 4ºC until further 
use. 
 
3.3. Pre-treatment with Cholera Toxin Subunit B (CTxB) 
The breast, colon and lung human cancer cell lines used in this project were plated 
in 6-well plates with 5x105 MCF-7 and HT-29 cells/well, and 2x105 A549 cells/well. These 
cells were left to adhere and grow overnight in a CO2 incubator (5%) at 37ºC. The 
following day, medium was collected and cells were treated with 1μg/mL of CTxB 
(Invitrogen, Alexa Fluor® 488 conjugate) in DMEM during 10 minutes. After this time, 
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medium was again collected and cells were treated with 50μM of WT azurin or mutated 
protein in DMEM. The plates were placed for 30 minutes at 37ºC.  
 
3.3.1. Protein extraction and Western blot 
After 30 minutes, the plates were placed on ice and wells were washed twice with 
PBS 1x. Then, cells lysed in 100μL of Catenin Lysis Buffer (CLB; 1% Triton X-100, 1% 
Nonidet-P40 in deionized PBS) supplemented with 1:7 proteases inhibitor (Roche 
Diagnostics GmbH) and 1:100 phosphatases inhibitor (Cocktail 3, Sigma Aldrich) for 10 
minutes at 4°C. Then, the cells were scratched, collected and vortexed three times (10 
seconds each), centrifuged (14.000 rpm, 4°C, 10 minutes; B. Braun Sigma-Aldrich 2K15) 
and the pellet was discarded, collecting the supernatant containing proteins. The samples 
were transferred to a 96-well plates and they were quantified by a Quantification Protein 
Kit (Bradford, BioRad). The determination of the total protein concentration, per sample, 
was achieved through the use of a calibration curve, on which were used the absorbance 
values of standard samples of bovine serum albumin, whose concentrations are known 
(provided by the kit). 10µg of total protein per sample were prepared with Laemmli buffer. 
This buffer containing 2-mercaptoethanol (which reduces the disulfide bridges of proteins, 
allowing the correct separation), Sodium Dodecyl Sulphate (detergent that binds the 
positive charges of proteins, giving a negative charge similar to all global so that they are 
separated only by molecular weight), bromophenol blue (dye acts as monitor the migration 
of the samples) and glycerol (increases the density of the sample so that it reaches the 
bottom).  
Next, samples were denatured at 95ºC during 5 minutes, and then separated by 
electrophoresis in a SDS-PAGE (Table 1). 
 
Table 1: SDS-PAGE components. 
 
The resulting SDS-PAGE gel electrophoresis was transferred to a nitrocellulose 
membrane (RTA Transfer Kit, BioRad). To this it was used a Trans-Blot® Turbo Transfer 
 15% Gel Resolving (µL) 5% Gel Stacking (µL) 
H2O 850 1700 
30% Acrilamide 1900 415 
Tris 1.5 M; pH 8.8 950 - 
Tris 10 M; pH 6.8 - 315 
10%  Sodium Dodecyl Sulphate 34 25 
10%  Ammonium Persulfate 34 25 
TEMED 1.5 2.5 
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System (BioRad), establishing an electric current through the gel and nitrocellulose 
membrane. 
The visualization of the bands with proteins, on the membrane, was achieved by the 
addition of Ponceau S, which binds positively charged amine groups of proteins.  After 
blocking the non-specific binding sites for 1 hour with 5% (w/v) not-fat dry milk in PBS-
Tween-20 (0.5% v/v), the membranes were incubated in an agitator overnight at 4°C with 
different primary antibodies (custom-made anti-azurin Ab [SicGen] and anti-GAPDH [H-12; 
Santa Cruz Biotechnology], diluted 1:500 and 1:1000 in 5% non-fat milk buffer, 
respectively).  
In the next day, the membranes were washed three times with PBS-Tween-20 
(0.5% v/v) for 5 minutes and probed with the appropriated secondary antibody, conjugated 
with horseradish peroxidase (mouse anti-goat IgG-HRP [Santa Cruz Biotechnology] for 
azurin and goat anti-mouse IgG-HRP [Santa Cruz Biotechnology] for GAPDH, both diluted 
1:2000 in 0.5% PSB Tween-20) at room temperature for 1 hour, in an agitator. After, the 
membranes were washed five times with PBS-Tween-20 for 5 minutes and were 
developed by adding ECL substrates (dilution 1:1; Pierce) and capture the 
chemiluminescence by Fusion Solo (Vilber Lourmat) equipment. The obtained images 
were analyzed with the Image J program and the protein levels were normalized by the 
respective GAPDH level. 
 
3.4. Confocal microscopy-Cholera Toxin Subunit B (CTxB) 
MCF-7, A549 and HT-29 cell lines were seeded on a round glass coverslip in 24-
well plates with 5x104 cells/well for the first two lines and 2x104 cells/well for the last line. 
These cells were left to adhere and grow overnight in a CO2 incubator (5%) at 37ºC.  
In the next day, medium was collected and cells were treated with 100μM of WT 
azurin or mutated protein in medium containing 10% FBS and 1% PenStrep. The plates 
were placed for 24 hours at 37ºC. After this time, medium was again collected and cells 
were treated with 1μg/mL of CTxB (Invitrogen, Alexa Fluor® 594 conjugate) in DMEM 
during 10 minutes. Afterwards, the coverslips were rinsed three times with PBS 1x. For 
fixation, cells in coverslips were immersed in 3.7% formaldehyde for 20 minutes at room 
temperature. After washed seven times in PBS 1x, the coverslips were mounted with 
Vectashield with DAPI and observed in confocal microscope (Leica Microsystems CMS 
GmbH; model no. DMI6000) with a 63x water (1.2-numerical-aperture) apochromatic 
objective. 
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3.5. Transfection of human cancer cells lines 
MCF-7 and A549 cell lines were plated in 6-well plates with 5x105 cells/well. These 
cells were left to adhere and grow overnight in a CO2 incubator (5%) at 37ºC.  
Prior to transfection, 100nM of Control siRNA (Santa Cruz Biotechnology) and 
Caveolin-1 siRNA (Santa Cruz Biotechnology) were mixed with Lipofectamine® 2000 
(Thermo Fisher Scientific). For this, 25µL of each siRNA were added to 225µL of DMEM 
and 10µL of Lipofectamine® 2000 were added to 240µL of the same medium, according to 
the manufacturer’s instructions. After 5 minutes, the prepared solutions were mixed gently 
to form siRNA-lipofectamine complex. This mixture was incubated for 20 minutes at room 
temperature and added to 2mL of DMEM in the respective well. After 6-8 hours in a CO2 
incubator (5%) at 37ºC, the medium was removed and fresh medium containing 10% FBS 
and 1% PenStrep was added to each well. The appropriate time for observing the 
decrease in the Cav1 protein levels was determined by Western blot, determining that 24 
hours post-transfection was adequate to perform the azurin entry assay. After this time, 
cells were treated with 50μM of WT azurin or mutated protein. The plates were placed for 
30 minutes at 37ºC. To determine the levels of azurin entry in Cav1-silenced cells, a 
Western blot was performed as described above (Section 3.3.1.). In this case, 20µg of 
total protein per sample were prepared with Laemmli buffer and in addition to the primary 
antibodies used in the above assay, it was also used an anti-actin primary antibody (Santa 
Cruz Biotechnology), and an anti-caveolin-1 primary antibody (Santa Cruz Biotechnology) 
to verify whether there was an inhibition in the expression of this protein, both diluted 
1:1000 in 5% non-fat milk. The secondary antibodies used against anti-actin and anti-
caveolin-1 primary antibodies were mouse anti-goat IgG-HRP (Santa Cruz Biotechnology) 
and goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology). Both diluted 1:2000 in 0.5% 
PBS-Tween-20. 
 
3.6. Interaction between Cav1-CSD and azurin 
To observe the interaction between the Caveolin-1 Scaffolding Domain (CSD; 
amino acids 82-101 of Cav1; Tourkina et al., 2008) and WT and mutated azurins, we 
made used of Fluorescein-5-IsoThioCyanate (FITC)-labeled CSD peptide (Pepmic). 
In this experiment, it was chosen 1µM of CSD concentration that is within the 
detection limits of the spectrofluorimeter and decreases the probability of peptide 
aggregation. The WT and mutated azurins’ concentrations were 0, 0.25, 0.5, 1, 5, 10 and 
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50µM. Three replicates for each of the proteins used were performed in 0.1M Sodium 
Phosphate Buffer (77.4mL of 1M Na2HPO4, 22.6mL of 1M NaH2PO4 and 900mL of H2O). 
This buffer does not contain NaCl, which could contribute to aggregation of the CSD, since 
this is a very hydrophobic peptide. Prior to observe the changed in fluorescence intensity 
of the peptide, the preparations with the peptide (CSD), protein (WT azurin or mutated 
protein) in 0.1M Sodium Phosphate Buffer were kept at 37ºC for 30 minutes to mimic the 
entry assay of these proteins in human cancer cell lines in study. 
Fluorescence measurements were carried out with a SLMAminco 8100 Series 2 
spectrofluorimeter (Rochester) with double excitation and emission monochromators (MC-
400), in a rightangle geometry. The light source was a 450-W Xe arc lamp and the 
reference a Rhodamine B quantum counter solution. Quartz cuvettes (1×1cm) from Hellma 
Analytics were used.  
Fluorescence intensities were obtained by excitation at 485nm and fluorescence 
emission collection between 490 and 600nm, wavelengths range suitable for FITC probe 
which is connected to the CSD. For every wavelengths it was attributed a single 
fluorescence intensity according to the protein concentration (WT azurin or mutated 
protein). The total fluorescence intensity for every protein concentration was calculated as 
the SUM of the intensity for each wavelengths, normalized to the intensity of the peptide 
alone, to which was subtracted the intensity without CSD. With the application of a 
polynomial adjust model, it was possible to trace a graphic to obtain a slope, which led to 
the calculus of the dissociation constant (Kd). This constant allows to study the affinity 
degree which the protein have to the peptide. 
 
3.7. MTT cell viability assay 
MTT [3-(4,5 dimethylthiazol-2-yl-2,5 tetrazolium bromide)] assays were used to 
determine the proliferation rate of MCF-7, HT-29 and A549 human cancer cells lines after 
they were treated with WT azurin combined with drugs. The drugs used in these assays 
were paclitaxel, an antimitotic agent, and doxorubicin, a DNA-damaging drug (Sigma Life 
Science). All these cell lines were seeded in 96-well plates (3 replicates) with a density of 
2x104 MCF-7 cells/well, 5x103 A549 cells/well and 1x104 HT-29 cells/well. These cells 
were left to adhere and grow overnight in a CO2 incubator (5%) at 37ºC.  
In the next day, medium was collected and cells were treated with 25, 50 and 
100μM of WT azurin together with 0.1, 1 and 10nM of paclitaxel or 0.1, 0.5 and 1 µM of 
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doxorubicin in medium containing 10% FBS and 1% PenStrep. The plates were placed for 
72 hours at 37ºC. 
After this time, 20μL of MMT reagent (5mg/mL) were added to each well and 
incubated at 37ºC for 3.5 hours. Reaction was stopped with the addition of 150μL of a 
solution 40mM HCL in isopropanol. MTT formazan formed was spectrophotometrically 
read at 590nm in a microplate reader (SpectroStarNano, BMG LABTECH). Untreated cells 
were used as control, in order to determine the relative cell viability of treated cells. 
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4. RESULTS / DISCUSSION / CONCLUSION AND FUTURE 
PERSPECTIVES 
Results of this work are subjected to a confidentially agreement. Consequently, they 
are presented in the confidentiality appendix, which are only available in the confidential 
version of the thesis. 
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